BIRC5 and glioblastoma: Similarly, Xia et al. used bioinformatics and network pharmacology to determine the inhibition mechanism of luteolin on the proliferation and migration of glioblastoma cells through the key targets BIRC5 and CCNB1, which impacted the prognosis of patients with glioblastoma (Xia Z. et al., 2022b).